NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis $88.32 -4.66 (-5.01%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$88.90 +0.58 (+0.66%) As of 05/29/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rhythm Pharmaceuticals alerts:Sign Up Key Stats Today's Range$87.98▼$93.5050-Day Range$75.82▼$96.6152-Week Range$60.06▼$122.20Volume757,902 shsAverage Volume764,520 shsMarket Capitalization$6.05 billionP/E RatioN/ADividend YieldN/APrice Target$131.81Consensus RatingModerate Buy Company Overview Rhythm Pharmaceuticals, Inc. is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation. The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1. Rhythm has advanced multiple Phase 3 clinical trials for setmelanotide and is pursuing regulatory approvals in both the United States and the European Union. In addition to its lead program, the company is exploring opportunities in related rare obesity indications and branching into other metabolic disorders tied to melanocortin pathway dysfunction. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals is led by a management team with extensive experience in drug development, regulatory strategy and commercialization of therapies for rare diseases. The company maintains a robust intellectual property portfolio around its peptide technology and collaborates with academic institutions and patient advocacy groups to advance understanding of rare genetic forms of obesity. Rhythm’s work underscores a commitment to precision medicine approaches that address the root causes of metabolic disorders.AI Generated. May Contain Errors. Read More Rhythm Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreRYTM MarketRank™: Rhythm Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 500th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 14 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRhythm Pharmaceuticals has a consensus price target of $131.81, representing about 49.2% upside from its current price of $88.32.Amount of Analyst CoverageRhythm Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.18) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -28.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 49.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.84% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 8.28.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 2.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.31 News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $502,790.00 in company stock.Percentage Held by Insiders5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.Percentage Held by InstitutionsRhythm Pharmaceuticals has minimal institutional ownership at this time.Read more about Rhythm Pharmaceuticals' insider trading history. Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RYTM Stock News HeadlinesRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026May 29 at 8:00 AM | globenewswire.comRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsMay 28 at 8:00 AM | globenewswire.com$7.7 billion in 90 days — and it all depends on ONE companySpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not software, but power infrastructure. The filing shows $23.85 billion in servers and $14 billion in construction in progress, all dependent on one company's hardware. Without this supplier, Colossus doesn't run and the $1.25 billion Anthropic pays monthly stops flowing. The stock is still trading like no one has read the filing - but analyst Dylan Jovine has, and he's releasing the name at no cost.May 30 at 1:00 AM | Behind the Markets (Ad)Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from AnalystsMay 28 at 4:13 AM | americanbankingnews.comRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)May 22, 2026 | theglobeandmail.comRhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyMay 12, 2026 | markets.businessinsider.comSee More Headlines RYTM Stock Analysis - Frequently Asked Questions How have RYTM shares performed this year? Rhythm Pharmaceuticals' stock was trading at $107.04 at the beginning of the year. Since then, RYTM shares have decreased by 17.5% and is now trading at $88.32. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. The company's revenue was up 83.8% on a year-over-year basis. Read the conference call transcript. When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $106 million in an initial public offering on Thursday, October 5th 2017. The company issued 7,050,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' top institutional investors include Perceptive Advisors LLC (3.46%), Janus Henderson Group PLC (1.34%), Siren L.L.C. (1.06%) and Rock Springs Capital Management LP (1.01%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, Jennifer Kayden Lee, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/05/2026Today5/30/2026Jefferies Global Healthcare Conference 20266/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RYTM's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RYTM CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees140Year Founded2008Price Target and Rating Average Price Target for Rhythm Pharmaceuticals$131.81 High Price Target$157.00 Low Price Target$88.00 Potential Upside/Downside+49.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$196.54 million Net Margins-93.33% Pretax Margin-92.89% Return on Equity-203.25% Return on Assets-44.99% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio3.89 Sales & Book Value Annual Sales$217.17 million Price / Sales27.87 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book49.34Miscellaneous Outstanding Shares68,533,000Free Float64,490,000Market Cap$6.05 billion OptionableOptionable Beta1.94 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RYTM) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredWhen SpaceX goes public your retirement pays the priceWhen SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...Reagan Gold Group | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
